Be Biopharma IPO

Be Biopharma (“Be Bio”) is pioneering Engineered B Cell Medicines (BeCM) to dramatically improve patients’ lives who are living with cancer, rare diseases and other serious conditions. The company's medicines address major hurdles of cell and gene therapies, and are durable, re-disable, and can be administered without toxic conditioning, thereby enabling healthcare sectors and patients to treat diseases like cancer, autoimmune conditions, and an enzyme deficiency. Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity. Be Bio was founded in October 2020 by Longwood Fund and B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D. from Seattle Children’s Research Institute.

Register for Details

For more details on financing and valuation for Be Biopharma, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Be Biopharma

Forge green plus iconForge green minus icon

Is Be Biopharma a publicly traded company?

Be Biopharma is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Forge green plus iconForge green minus icon

Will Be Biopharma go IPO?

Be Biopharma has not yet filed for an IPO. However, it's important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or through mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2024.

Forge green plus iconForge green minus icon

What is Be Biopharma's IPO price?

The IPO price for Be Biopharma will be known only if it becomes public. However, you may access the "Price At Last Round" and the "Implied EV" for publicly traded comparable companies with Forge Data.
Forge green plus iconForge green minus icon

Can you invest in Be Biopharma pre-IPO?

Be Biopharma is privately held company and is not publicly traded, therefor investing in Be Biopharma pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to invest in private companies before their potential IPO. If you are not an accredited investor, discover how to begin the the process to potentially qualify for new investment opportunities.

Forge green plus iconForge green minus icon

What is the value of my Be Biopharma shares?

To determine the value of your Be Biopharma shares, create a free account to gain access to Forge’s platform. Forge Markets contains pricing information for hundreds of pre-IPO companies. A Private Market Specialist will also be available to assist you with any inquiries related to your Be Biopharma shares. You can also learn more about how to sell your private shares before getting started.

Forge green plus iconForge green minus icon

Can you sell Be Biopharma before it goes public?

Yes, you can seek to sell shares in Be Biopharma while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.

Forge green plus iconForge green minus icon

What is Be Biopharma's funding to date?

Be Biopharma has raised $182.1MM to date.
Forge green plus iconForge green minus icon

When was Be Biopharma founded?

Be Biopharma was founded in 2020.

Who are Be Biopharma's major investors?

Atlas Venture
Ra Capital Management
Longwood Fund
Alta Partners
Takeda Ventures
Arch Venture Partners
Bristol Myers Squibb

Be Biopharma funding rounds and last known valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation

Series B

$118MM raised $XXX.XX $XXX.XX

Series A

$64.1MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data
Updated on: Jul 25, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.